MV-140 Efficacy in Recurrent Urinary Tract Infections in a Cohort of Portuguese Adult Patients

Urinary Tract Infections Clinical Trial

Official title: MV-140 Efficacy in Recurrent Urinary Tract Infections

Status Active, not recruiting

Clinical Trial Summary

We will access the efficacy of MV-140 immunotherapy in the prevention of recurrent urinary tract infections in a cohort of Portuguese patients.

Clinical Trial Description

Urinary tract infections represent a highly frequent and debilitating disease, responsible for an extensive use of antibiotics for treatment and prophylaxis. Non-antibiotic therapies, such as oral vaccines, have been developed, in order to avoid antibiotic use. MV-140 is a sublingual vaccine comprised of 4 inactivated bacteria - E. coli, K. pneumoniae, E. faecalis and Proteus vulgaris. It is approved for the prevention of recurrent UTIs, with promising results in the few published results to date. The efficacy of this tool in the Portuguese population is, however, still unknown. Since the prevalence of pathogens responsible for infections and overall antibiotic use are highly variable worldwide, the results of studies conducted so far are not directly applicable in other regions. Therefore, we designed the present study which aims at assessing the efficacy of immunotherapy with MV-140 In the Portuguese population. It is a prospective observational study, in which patients will be asked to report their condition before and 1 year after therapy. ;

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Urinary Tract Infections

• NCT number: NCT06392282
• Study type: Observational [Patient Registry]
• Source: Unidade Local de Saúde Santa Maria
• Status: Active, not recruiting
• Start date: June 1, 2023
• Completion date: May 1, 2024